To hear about similar clinical trials, please enter your email below

Trial Title: DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT ID: NCT05504707

Condition: Triple Negative Breast Cancer
HER2-negative Breast Cancer

Conditions: Official terms:
Breast Neoplasms
Triple Negative Breast Neoplasms

Conditions: Keywords:
Breast Cancer

Study type: Interventional

Study phase: Phase 1

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Sequential Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Biological
Intervention name: HER2 - primed Dendritic cells
Description: Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs. Participants will be treated at the following dose levels: Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million
Arm group label: Dendritic Cell Vaccine dose Escalation

Intervention type: Biological
Intervention name: HER3 - primed Dendritic cells
Description: Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs. Participants will be treated at the following dose levels: Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million
Arm group label: Dendritic Cell Vaccine dose Escalation

Summary: The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - A diagnosis of HER2-negative breast cancer. - Diagnosis of HR negative or HR low positive tumor. - Clinical stage T1c, nodal stage N1-N2 or stage T2-4, nodal stage N0-N2 breast cancer. - Participant must be medically and surgically appropriate to undergo neoadjuvant chemotherapy regimen followed by standard of care local therapy as determined by their treating physician. - Age ≥18 years. - ECOG performance status 0 or 1. - Patients must have normal organ and marrow function, as defined below, within 14 days of registration: - *Absolute neutrophil count (ANC) ≥ 1500/μL - *Platelets ≥ 75 000/μL - *Total bilirubin ≤ 1.5 x institutional ULN, except patients with Gilbert's syndrome in whom total bilirubin must be < 3.0 mg/dL - *AST/ALT ≤ 3 x institutional ULN - *Creatinine ≤ 1.5 x institutional ULN - Left ventricular ejection fraction above institutional lower limit of normal (by echocardiogram or MUGA scan). - Female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Effective methods of contraception must be used throughout the study and for 5 months following the last dose. To show that women do not have childbearing potential, postmenopausal women must be amenorrheic for at least 12 months naturally (and not because of/following chemotherapy) or patients must be surgically sterile. - Ability to understand and the willingness to sign a written informed consent agreement prior to study registration. Exclusion Criteria: - Patients who received prior anthracycline-based chemotherapy for the treatment of any cancer. - Patients with inflammatory breast cancer. - Patients must not be receiving any other investigational agents or active antineoplastic therapies. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune-suppressive treatment, including chronic prolonged systemic corticosteroid use (defined as corticosteroid use lasting one month or more). - Female patients who are pregnant or nursing. - No other prior malignancy is allowed, except for the following: a. adequately treated basal-cell or squamous-cell skin cancer, b. in situ cervical cancer, c. or any other cancer from which the patient has been disease free for at least 3 years. - History of testing positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). - History of positive test for Hepatitis B or Hepatitis C virus indicating acute or chronic infection. - Patients who have received a live attenuated vaccine ≤ 30 days prior to registration. - Unable to comply with the treatment schedule and study procedures for any reason. - Previously treated with breast cancer-directed vaccine therapies in prior 3 months. - Previously treated with any form HER2- or HER3-primed DC1 therapy.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Moffitt Cancer Center

Address:
City: Tampa
Zip: 33612
Country: United States

Status: Recruiting

Contact:
Last name: Jennifer Childress
Email: Jennifer.Childress@moffitt.org

Investigator:
Last name: Ricardo Costa, MD, MSc
Email: Principal Investigator

Investigator:
Last name: Brian Czerniecki, MD, PhD
Email: Sub-Investigator

Start date: August 26, 2022

Completion date: October 2025

Lead sponsor:
Agency: H. Lee Moffitt Cancer Center and Research Institute
Agency class: Other

Collaborator:
Agency: The Shulas' Foundation
Agency class: Other

Source: H. Lee Moffitt Cancer Center and Research Institute

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05504707
https://moffitt.org/clinical-trials-research/clinical-trials/?gclid=EAIaIQobChMImIymzIa-9gIVAZ2GCh3uzAWJEAAYASAAEgI0ovD_BwE

Login to your account

Did you forget your password?